OneSource Specialty Pharma Limited has issued a clarification regarding the delay in commercial supplies of Semaglutide, as previously intimated by Dr. Reddy’s Laboratories (DRL). OneSource, a manufacturing partner for Generic Semaglutide Injection with DRL, stated that the delay disclosed by DRL will not have any material financial or operational impact on its own business. The company affirmed its commitment to its partnership with DRL and highlighted that it has substantial demand from other customers, including for the Canadian market, with its current capacities fully committed. Furthermore, OneSource is expanding its capacities, with new facilities coming online starting in the current quarter and later in the year, ensuring it can meet DRL's demand once supplies resume. OneSource Specialty Pharma remains focused on its growth strategies and providing high-quality, reliable, and continuous supply to its global clientele.
